Cited by 557CRISPR and Genetic EngineeringAcute Myeloid Leukemia ResearchChromatin Remodeling and Cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing

Open access

Heckl, Dirk, Kowalczyk, Monika S, Yudovich, David, Belizaire, Roger, Puram, Rishi V, McConkey, Marie E, Thielke, Anne, Aster, Jon C, Regev, Aviv, Ebert, Benjamin L·2014·Nature Biotechnology

DOI 10.1038/nbt.2951PMC PMC4160386

Open this paper in CoChat — free account

Abstract

Genome sequencing studies have shown that human malignancies often bear mutations in four or more driver genes, but it is difficult to recapitulate this degree of genetic complexity in mouse models using conventional breeding. Here we use the CRISPR-Cas9 system of genome editing to overcome this limitation. By delivering combinations of small guide RNAs (sgRNAs) and Cas9 with a lentiviral vector, we modified up to five genes in a single mouse hematopoietic stem cell (HSC), leading to clonal outgrowth and myeloid malignancy. We thereby generated models of acute myeloid leukemia (AML) with cooperating mutations in genes encoding epigenetic modifiers, transcription factors and mediators of cytokine signaling, recapitulating the combinations of mutations observed in patients. Our results suggest that lentivirus-delivered sgRNA:Cas9 genome editing should be useful to engineer a broad array of in vivo cancer models that better reflect the complexity of human disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nbt.2951

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citation
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
One-step generation of mice carrying mutations in multiple genes by CRISPR/Cas-mediated genome engineering
Wang, H., Yang, H., Shivalila, C. S., Dawlaty, M. M., Cheng, A. W., Zhang, F., & Jaenisch, R. (2013) · Cell · doi:10.1016/j.cell.2013.04.025 · Cited by 3,495
High-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Efficient genome editing in zebrafish using a CRISPR-Cas system
Hwang, W. Y., Fu, Y., Reyon, D., Maeder, M. L., Tsai, S. Q., Sander, J. D., Peterson, R. T., Yeh, J.-R. J., & Joung, J. K. (2013) · Nature Biotechnology · doi:10.1038/nbt.2501 · Cited by 2,937
Genetic screens in human cells using the CRISPR-Cas9 system
Wang, T., Wei, J. J., Sabatini, D. M., & Lander, E. S. (2014) · Science · doi:10.1126/science.1246981 · Cited by 2,856

Flagged first, then by citations

Show all 27 references

Sorted by citations

Items 101–200 of 557

Modeling the process of human tumorigenesis
Balani, S., Nguyen, L. V., & Eaves, C. J. (2017) · Nature Communications · doi:10.1038/ncomms15422 · Cited by 80
Generation and comparison of CRISPR-Cas9 and Cre-mediated genetically engineered mouse models of sarcoma
Huang, J., Chen, M., Whitley, M. J., Kuo, H.-C., Xu, E. S., Walens, A., Mowery, Y. M., Mater, D. V., Eward, W. C., Cardona, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15999 · Cited by 75
ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts
Valletta, S., Dolatshad, H., Bartenstein, M., Yip, B. H., Bello, E., Gordon, S. A. K., Yu, Y., Shaw, J. M., Roy, S., Scifo, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6392 · Cited by 75
Genome Editing and Its Applications in Model Organisms
Ma, D., & Liu, F. (2015) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.12.001 · Cited by 81
CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo
Reimer, J., Knöß, S., Labuhn, M., Charpentier, E., Göhring, G., Schlegelberger, B., Klusmann, J., & Heckl, D. (2017) · Haematologica · doi:10.3324/haematol.2017.164046 · Cited by 75
Self-citation
Applications of CRISPR-Cas9 as an Advanced Genome Editing System in Life Sciences
Tavakoli, K., Pour‐Aboughadareh, A., Kianersi, F., Poczai, P., Etminan, A., & Shooshtari, L. (2021) · BioTech · doi:10.3390/biotech10030014 · Cited by 84
Integrated Phosphoproteome and Transcriptome Analysis Reveals Chlamydia-Induced Epithelial-to-Mesenchymal Transition in Host Cells
Zadora, P. K., Chumduri, C., Imami, K., Berger, H., Mi, Y., Selbach, M., Meyer, T. F., & Gurumurthy, R. K. (2018) · Cell Reports · doi:10.1016/j.celrep.2019.01.006 · Cited by 70
Rapid Generation of Somatic Mouse Mosaics with Locus-Specific, Stably Integrated Transgenic Elements
Kim, G. B., Pacheco, D. R. F., Saxon, D. S., Yang, A., Sabet, S., Dutra‐Clarke, M., Levy, R., Watkins, A., Park, H., Akhtar, A. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.013 · Cited by 74
High-throughput identification of autoantibodies that target the human exoproteome
Wang, E. Y., Dai, Y., Rosen, C. E., Schmitt, M. M., Dong, M. X., Ferré, E. M. N., Liu, F., Yang, Y., González-Hernández, J. A., Meffre, E., et al. (2022) · Cell Reports Methods · doi:10.1016/j.crmeth.2022.100172 · Cited by 76
A versatile modular vector system for rapid combinatorial mammalian genetics
Albers, J., Danzer, C., Rechsteiner, M., Lehmann, H., Brandt, L. P., Hejhal, T., Catalano, A., Busenhart, P., Gonçalves, A. F., Brandt, S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79743 · Cited by 73
Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin
Ravi, N. S., Wienert, B., Wyman, S. K., Bell, H. W., George, A., Mahalingam, G., Vu, J. T., Prasad, K. M., Bandlamudi, B. P., Devaraju, N., et al. (2022) · eLife · doi:10.7554/elife.65421 · Cited by 70
Murine Models of Acute Myeloid Leukaemia
Almosailleakh, M., & Schwaller, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20020453 · Cited by 74
Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma
Ng, Y. L. D., Ramberger, E., Bohl, S., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28515-1 · Cited by 68
EZH2 in Myeloid Malignancies
Rinke, J., Chase, A., Cross, N. C. P., Hochhaus, A., & Ernst, T. (2020) · Cells · doi:10.3390/cells9071639 · Cited by 71
CRISPR-Cas9-Based Technology and Its Relevance to Gene Editing in Parkinson’s Disease
Rahman, M. U., Bilal, M., Shah, J. A., Kaushik, A. K., Teissèdre, P., & Kujawska, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061252 · Cited by 65
Application of CRISPR/Cas9 genome editing to the study and treatment of disease
Pellagatti, A., Dolatshad, H., Valletta, S., & Boultwood, J. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1504-y · Cited by 65
The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability
Huang, Y., Mouttet, B., Warnatz, H.-J., Risch, T., Rietmann, F., Frommelt, F., Ngo, Q. A., Dobay, M. P., Marovca, B., Jenni, S., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.004 · Cited by 63
ROS-induced cleavage of NHLRC2 by caspase-8 leads to apoptotic cell death in the HCT116 human colon cancer cell line
Nishi, K., Iwaihara, Y., Tsunoda, T., Doi, K., Sakata, T., Shirasawa, S., & Ishikura, S. (2017) · Cell Death and Disease · doi:10.1038/s41419-017-0006-7 · Cited by 62
MLL leukemia induction by genome editing of human CD34+ hematopoietic cells
Buechele, C., Breese, E. H., Schneidawind, D., Lin, C.-H., Jeong, J., Duque-Afonso, J., Wong, S. H. K., Smith, K. S., Negrin, R. S., Porteus, M., et al. (2015) · Blood · doi:10.1182/blood-2015-05-646398 · Cited by 60
miR-130a Deregulates PTEN and Stimulates Tumor Growth
Wei, H., Cui, R., Bahr, J. C., Zanesi, N., Luo, Z., Meng, W., Liang, G., & Croce, C. M. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0530 · Cited by 62
CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment
Xing, H., & Meng, L. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0322-9 · Cited by 61
The stem cell–specific long noncoding RNA HOXA10-AS in the pathogenesis of KMT2A-rearranged leukemia
Neyazi, S., Bhayadia, R., Ng, M. S. W., Verboon, L., Emmrich, S., Gack, L., Schwarzer, A., Strowig, T., Heckl, D., & Klusmann, J. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019032029 · Cited by 58
Self-citation
A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment
Yang, X., & Zhang, B. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01117-w · Cited by 58
Transient Retrovirus-Based CRISPR/Cas9 All-in-One Particles for Efficient, Targeted Gene Knockout
Knopp, Y., Geis, F. K., Heckl, D., Horn, S., Neumann, T., Kuehle, J., Meyer, J., Fehse, B., Baum, C., Morgan, M. A., et al. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.09.006 · Cited by 63
Self-citation
Progress and challenges towards CRISPR/Cas clinical translation
Rosenblum, D., Gutkin, A., Dammes, N., & Peer, D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.004 · Cited by 61
Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia
Lazarian, G., Guièze, R., & Wu, C. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.0822 · Cited by 58
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia
Dieck, C. L., Tzoneva, G., Forouhar, F., Carpenter, Z., Ambesi‐Impiombato, A., Sánchez-Martín, M., Kirschner‐Schwabe, R., Lew, S., Seetharaman, J., Tong, L., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.003 · Cited by 57
RNA-Binding Proteins in Acute Leukemias
Schuschel, K., Helwig, M., Hüttelmaier, S., Heckl, D., Klusmann, J., & Hoell, J. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103409 · Cited by 57
Self-citation
CRISPR/Cas9: From Genome Engineering to Cancer Drug Discovery
Luo, J. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.001 · Cited by 57
Efficient homing of T cells via afferent lymphatics requires mechanical arrest and integrin-supported chemokine guidance
Martens, R., Permanyer, M., Werth, K., Yu, K., Braun, A., Halle, O., Halle, S., Patzer, G. E., Bošnjak, B., Kiefer, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14921-w · Cited by 55
Polysialic acid and Siglec-E orchestrate negative feedback regulation of microglia activation
Thiesler, H., Beimdiek, J., & Hildebrandt, H. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03601-z · Cited by 55
A potential paradigm in CRISPR/Cas systems delivery: at the crossroad of microalgal gene editing and algal-mediated nanoparticles
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 59
Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles
Yu, K., Natanson, H., & Dunbar, C. E. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.107 · Cited by 59
The Zinc Finger Antiviral Protein ZAP Restricts Human Cytomegalovirus and Selectively Binds and Destabilizes Viral UL4 / UL5 Transcripts
Gonzalez-Perez, A. C., Stempel, M., Wyler, E., Urban, C., Piras, A., Hennig, T., Ganskih, S., Wei, Y., Heim, A., Landthaler, M., et al. (2021) · mBio · doi:10.1128/mbio.02683-20 · Cited by 57
OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis
Lee, S.-A., Chang, L.-C., Jung, W., Bowman, J. W., Kim, D.-K., Chen, W., Foo, S., Choi, Y. J., Choi, U. Y., Bowling, A., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-022-01039-y · Cited by 55
Using RNA as Molecular Code for Programming Cellular Function
Kushwaha, M., Rostain, W., Prakash, S., Duncan, J. N., & Jaramillo, A. (2016) · ACS Synthetic Biology · doi:10.1021/acssynbio.5b00297 · Cited by 56
Self-reactive CD4+ IL-3+ T cells amplify autoimmune inflammation in myocarditis by inciting monocyte chemotaxis
Anzai, A., Mindur, J. E., Halle, L., Sano, S., Choi, J. L., He, S., McAlpine, C. S., Chan, C. T., Kahles, F., Valet, C., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20180722 · Cited by 55
Deciphering the RAS/ERK pathway in vivo
Dorard, C., Vucak, G., & Baccarini, M. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160135 · Cited by 53
Approach for in vivo delivery of CRISPR/Cas system: a recent update and future prospect
Chuang, Y.-F., Phipps, A. J., Lin, F., Hecht, V. F. G., Hewitt, A. W., Wang, P., & Liu, G. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03725-2 · Cited by 53
The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma
Ren, Z., Lantermans, H. C., Kuil, A., Kraan, W., Arenzana‐Seisdedos, F., Kersten, M. J., Spaargaren, M., & Pals, S. T. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01031-3 · Cited by 52
FOSL1 Inhibits Type I Interferon Responses to Malaria and Viral Infections by Blocking TBK1 and TRAF3/TRIF Interactions
Cai, B., Wu, J., Yu, X. H., Su, X., & Wang, R.-F. (2017) · mBio · doi:10.1128/mbio.02161-16 · Cited by 55
HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes
Zhong, X., Prinz, A., Steger, J., García-Cuéllar, M.-P., Radsak, M. P., Bentaher, A., & Slany, R. K. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018025866 · Cited by 52
Targeting cell cycle and apoptosis to overcome chemotherapy resistance in acute myeloid leukemia
Ling, V., Straube, J., Godfrey, W. A., Haldar, R., Janardhanan, Y., Cooper, L. T., Bruedigam, C., Cooper, E., Shirazi, P. T., Jacquelin, S., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01755-2 · Cited by 49
CRISPR-Cas9: a promising genetic engineering approach in cancer research
Ratan, Z. A., Son, Y., Haidere, M. F., Uddin, B. M. M., Yusuf, M. A., Zaman, S. B., Kim, J., Banu, L. A., & Cho, J. Y. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834018755089 · Cited by 52
Retinoid-Sensitive Epigenetic Regulation of the Hoxb Cluster Maintains Normal Hematopoiesis and Inhibits Leukemogenesis
Qian, P., Kumar, B. D., He, X., Nolte, C., Gogol, M., Ahn, Y., Chen, S., Li, Z., Xu, H., Perry, J. M., et al. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.04.012 · Cited by 51
CRISPR/Cas system: An emerging technology in stem cell research
Valenti, M. T., Serena, M., Carbonare, L. D., & Zipeto, D. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i11.937 · Cited by 54
Baboon Envelope Pseudotyped “Nanoblades” Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+ Cells
Gutiérrez-Guerrero, A., Abrey-Recalde, M. J., Mangeot, P. E., Costa, C., Bernadin, O., Perian, S., Fusil, F., Froment, G., Martinez-Turtos, A., Krug, A., et al. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.604371 · Cited by 59
Applications of Genome Editing Technology in Animal Disease Modeling and Gene Therapy
Li, Q., Qin, Z., Wang, Q., Xu, T., Yang, Y., & He, Z. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.05.006 · Cited by 52
Gene Therapy for Cardiovascular Disease: Basic Research and Clinical Prospects
Cao, G., Xuan, X., Zhang, R., Hu, J. H., & Dong, H. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.760140 · Cited by 58
CRISPR: a versatile tool for both forward and reverse genetics research
Gurumurthy, C. B., Grati, M., Ohtsuka, M., Schilit, S. L. P., Quadros, R. M., & Liu, X. Z. (2016) · Human Genetics · doi:10.1007/s00439-016-1704-4 · Cited by 52
Combined Human Genome-wide RNAi and Metabolite Analyses Identify IMPDH as a Host-Directed Target against Chlamydia Infection
Rother, M., Gonzalez, E., da Costa, A. R. T., Wask, L., Gravenstein, I., Pardo, M., Pietzke, M., Gurumurthy, R. K., Angermann, J., Laudeley, R., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.04.002 · Cited by 51
CRISPR: History and perspectives to the future
Kozovská, Z., Rajcaniova, S., Munteanu, P., Dzacovska, S., & Demková, L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111917 · Cited by 60
A branching model of lineage differentiation underpinning the neurogenic potential of enteric glia
Laddach, A., Chng, S. H., Lasrado, R., Progatzky, F., Shapiro, M., Erickson, A. G., Castañeda, M. S., Artemov, A. V., Bon‐Frauches, A. C., Amaniti, E.-M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41492-3 · Cited by 54
DNA-damage response in hematopoietic stem cells: an evolutionary trade-off between blood regeneration and leukemia suppression
Biechonski, S., Yassin, M., & Milyavsky, M. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx002 · Cited by 54
CRISPR therapeutic tools for complex genetic disorders and cancer (Review)
Baliou, S., Adamaki, M., Kyriakopoulos, A. M., Spandidos, D. A., Panayiotidis, M. I., Christodoulou, I., & Zoumpourlis, V. C. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4434 · Cited by 55
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
Saraç, H., Morova, T., Pires, E., McCullagh, J., Kaplan, A., Cingöz, A., Onder, T. B., Önder, T. T., Kawamura, A., & Lack, N. A. (2019) · Oncogene · doi:10.1038/s41388-019-1116-8 · Cited by 50
Transcriptional control of brain tumor stem cells by a carbohydrate binding protein
Sharanek, A., Burban, A., Hernández-Corchado, A., Madrigal, A., Fatakdawala, I., Najafabadi, H. S., Soleimani, V. D., & Jahani‐Asl, A. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109647 · Cited by 47
PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice
Weber, J., Rosa, J. D. L., Grove, C. S., Schick, M., Rad, L., Baranov, O., Strong, A., Pfaus, A., Friedrich, M., Engleitner, T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09180-3 · Cited by 51
Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Vesga, C. P. C., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2519 · Cited by 51
Progress and Perspective of CRISPR‐Cas9 Technology in Translational Medicine
Zheng, R., Zhang, L., Parvin, R., Su, L., Chi, J., Shi, K., Ye, F., & Huang, X. (2023) · Advanced Science · doi:10.1002/advs.202300195 · Cited by 56
CRISPR in Animals and Animal Models
Shrock, E., & Güell, M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.07.010 · Cited by 45
Use of CRISPR/Cas9 gene-editing tools for developing models in drug discovery
Ahmad, G., & Amiji, M. M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.014 · Cited by 48
CRISPR/Cas9: the Jedi against the dark empire of diseases
Khan, S., Mahmood, M. S., Rahman, S. U., Zafar, H., Khan, S. H., khan, Z., & Ahmad, A. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0425-5 · Cited by 49
Clonal Hematopoiesis and Its Impact on Cardiovascular Disease
Sano, S., Wang, Y., & Walsh, K. X. (2018) · Circulation Journal · doi:10.1253/circj.cj-18-0871 · Cited by 50
Development of delivery strategies for CRISPR‐Cas9 genome editing
Liu, Q., Yang, J., Xing, Y., Zhao, Y., & Liu, Y. (2023) · BMEMat · doi:10.1002/bmm2.12025 · Cited by 47
Genome editing strategies: potential tools for eradicating HIV-1/AIDS
Khalili, K., Kaminski, R., Gordon, J., Cosentino, L., & Hu, W. (2015) · Journal of NeuroVirology · doi:10.1007/s13365-014-0308-9 · Cited by 51
Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development
Tan, P., He, L., Xing, C., Jingrong, M., Yu, X. H., Zhu, M., Diao, L., Han, L., Zhou, Y., You, J. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127721 · Cited by 47
CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia
Ramakrishnan, R., Peña‐Martínez, P., Agarwal, P., Rodriguez‐Zabala, M., Chapellier, M., Högberg, C., Eriksson, M. D., Yudovich, D., Shah, M., Ehinger, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107684 · Cited by 46
Self-citation
X‐ray‐Guided In Situ Genetic Engineering of Macrophages for Sustained Cancer Immunotherapy
Zhao, C., Cheng, Y., Huang, P., Wang, C., Wang, W., Wang, M., Shan, W., & Deng, H. (2022) · Advanced Materials · doi:10.1002/adma.202208059 · Cited by 45
Genome-scale pan-cancer interrogation of lncRNA dependencies using CasRx
Montero, J. J., Trozzo, R., Sugden, M., Öllinger, R., Belka, A., Zhigalova, E., Waetzig, P., Engleitner, T., Schmidt‐Supprian, M., Saur, D., et al. (2024) · Nature Methods · doi:10.1038/s41592-024-02190-0 · Cited by 50
Programmable Molecular Scissors: Applications of a New Tool for Genome Editing in Biotech
Saha, S. K., Saikot, F. K., Rahman, M. S., Jamal, M. A. H. M., Rahman, S. M. K., Islam, S. M. R., & Kim, K. (2018) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2018.11.016 · Cited by 48
Application and perspective of CRISPR/Cas9 genome editing technology in human diseases modeling and gene therapy
Zhang, M., Li, H., & Jin, Y. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1364742 · Cited by 49
Untitled work
(2016) · doi:10.13918/j.issn.2095-8137.2016.4.191
The CRISPR/Cas9 system: Their delivery, in vivo and ex vivo applications and clinical development by startups
Song, M. (2017) · Biotechnology Progress · doi:10.1002/btpr.2484 · Cited by 46
Targeting the CaVα–CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy
Khanna, R., Yu, J., Yang, X.-F., Moutal, A., Chefdeville, A., Gokhale, V. M., Shuja, Z., Chew, L. A., Bellampalli, S. S., Luo, S., et al. (2019) · Pain · doi:10.1097/j.pain.0000000000001524 · Cited by 43
Developments in our understanding of the genetic basis of birth defects
Webber, D. M., MacLeod, S. L., Bamshad, M. J., Shaw, G. M., Finnell, R. H., Shete, S. S., Witte, J. S., Erickson, S. W., Murphy, L. D., & Hobbs, C. A. (2015) · Birth Defects Research Part A Clinical and Molecular Teratology · doi:10.1002/bdra.23385 · Cited by 44
Using CRISPR/Cas to study gene function and model disease in vivo
Tschaharganeh, D. F., Lowe, S. W., Garippa, R. J., & Livshits, G. (2016) · FEBS Journal · doi:10.1111/febs.13750 · Cited by 47
The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia
García‐Tuñón, I., Hernández‐Sánchez, M., Ordóñez, J. L., Alonso-Pérez, V., Quijada‐Álamo, M., Benito, R., Guerrero, C., Hernández‐Rivas, J. M., & Sánchez‐Martín, M. (2017) · Oncotarget · doi:10.18632/oncotarget.15215 · Cited by 41
Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes
McLemore, A. F., Hou, H., Meyer, B. S., Lam, N. B., Ward, G., Aldrich, A. L., Rodrigues, M. A., Vedder, A., Zhang, L., Padron, E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159430 · Cited by 42
Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS
Huang, Z., Tomitaka, A., Raymond, A., & Nair, M. (2017) · Gene Therapy · doi:10.1038/gt.2017.35 · Cited by 43
Effective Delivery of the CRISPR/Cas9 System Enabled by Functionalized Mesoporous Silica Nanoparticles for GFP‐Tagged Paxillin Knock‐In
Xu, X., Koivisto, O., Liu, C., Zhou, J., Miihkinen, M., Jacquemet, G., Wang, D., Rosenholm, J. M., Shu, Y., & Zhang, H. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000072 · Cited by 41
Oxidized mitochondrial DNA released after inflammasome activation is a disease biomarker for myelodysplastic syndromes
Ward, G., McGraw, K. L., Aghababazadeh, F. A., Meyer, B. S., McLemore, A. F., Vincelette, N. D., Lam, N. B., Aldrich, A. L., Ali, N. H. A., Padron, E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003475 · Cited by 42
A prolactin-dependent sexually dimorphic mechanism of migraine chronification
Ikegami, D., Navratilova, E., Yue, X., Moutal, A., Kopruszinski, C. M., Khanna, R., Patwardhan, A. M., Dodick, D. W., & Porreca, F. (2021) · Cephalalgia · doi:10.1177/03331024211039813 · Cited by 40
METTL18-mediated histidine methylation of RPL3 modulates translation elongation for proteostasis maintenance
Matsuura-Suzuki, E., Shimazu, T., Takahashi, M., Kotoshiba, K., Suzuki, T., Kashiwagi, K., Sohtome, Y., Akakabe, M., Sodeoka, M., Dohmae, N., et al. (2022) · eLife · doi:10.7554/elife.72780 · Cited by 42
Functional genomic screening approaches in mechanistic toxicology and potential future applications of CRISPR-Cas9
Shen, H. M., McHale, C. M., Smith, M. T., & Zhang, L. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2015.01.002 · Cited by 40
CRISPR‐Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies
Wen, W., Yuan, Z., Ma, S., Jiang, X., & Yuan, D. (2015) · International Journal of Cancer · doi:10.1002/ijc.29626 · Cited by 41
CRISPR/Cas9 editing of the genome for cancer modeling
Guernet, A. A., & Grumolato, L. (2017) · Methods · doi:10.1016/j.ymeth.2017.03.007 · Cited by 44
CRISPR to fix bad blood: a new tool in basic and clinical hematology
González-Romero, E., Martínez-Valiente, C., García-Ruiz, C., Vázquez‐Manrique, R. P., Cervera, J., & Sanjuán-Pla, A. (2019) · Haematologica · doi:10.3324/haematol.2018.211359 · Cited by 42
Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells
Lee, B., Lozano, R. J., & Dunbar, C. E. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.001 · Cited by 39
Genome-wide siRNA screen identifies UNC50 as a regulator of Shiga toxin 2 trafficking
Selyunin, A. S., Iles, L. R., Bartholomeusz, G. A., & Mukhopadhyay, S. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201704015 · Cited by 39
Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1
VanLith, C. J., Guthman, R. M., Nicolas, C. T., Allen, K. L., Du, Z., Joo, D. J., Nyberg, S. L., Lillegard, J. B., & Hickey, R. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.252 · Cited by 39
Modelling acute myeloid leukemia (AML): What’s new? A transition from the classical to the modern
Dozzo, A., Galvin, A., Shin, J., Scalia, S., O’Driscoll, C. M., & Ryan, K. B. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01189-4 · Cited by 40
CRISPR-Cas Technology as a Revolutionary Genome Editing tool: Mechanisms and Biomedical Applications
Ebrahimi, S., Khosravi, M. A., Raz, A., Karimipoor, M., & Parvizi, P. (2023) · ̒Ulūm va funūn-i bastah/bandī · doi:10.61186/ibj.27.5.219 · Cited by 40
Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1–HER3 signaling
Würth, R., Donato, E., Michel, L. L., Saini, M., Becker, L., Cheytan, T., Doncevic, D., Meßmer, T., Gutjahr, E., Weber, R., et al. (2025) · Nature Cancer · doi:10.1038/s43018-024-00882-2 · Cited by 37
Inactivation of Cancer Mutations Utilizing CRISPR/Cas9
Gebler, C., Lohoff, T., Paszkowski‐Rogacz, M., Mircetic, J., Chakraborty, D., Camgöz, A., Hamann, M. V., Theis, M., Thiede, C., & Buchholz, F. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw183 · Cited by 38
Binding of NUFIP2 to Roquin promotes recognition and regulation of ICOS mRNA
Rehage, N., Davydova, E., Conrad, C., Behrens, G., Maiser, A., Stehklein, J. E., Brenner, S., Klein, J., Jeridi, A., Hoffmann, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02582-1 · Cited by 36
Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy
Zhang, C., Peng, Y., Hublitz, P., Zhang, H., & Dong, T. (2018) · Scientific Reports · doi:10.1038/s41598-018-23803-7 · Cited by 36
Deubiquitinase OTUD5 is a positive regulator of mTORC1 and mTORC2 signaling pathways
Cho, J. H., Kim, K., Kim, S., Park, B.-O., Park, B.-O., Kim, J.-H., Kim, S., Kwon, M. J., Han, M., Lee, S. B., et al. (2020) · Cell Death and Differentiation · doi:10.1038/s41418-020-00649-z · Cited by 37
The PAF1 complex promotes 3′ processing of pervasive transcripts
Liu, X., Guo, Z., Han, J., Peng, B., Zhang, B., Li, H., Hu, X., David, C. J., & Chen, M. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110519 · Cited by 36
The retroviral vector family: something for everyone
Elsner, C., & Bohne, J. (2017) · Virus Genes · doi:10.1007/s11262-017-1489-0 · Cited by 36

Authors: Heckl, D., Kowalczyk, M. S., Yudovich, D., Belizaire, R., Puram, R. V., McConkey, M. E., Thielke, A., Aster, J. C., Regev, A., & Ebert, B. L.
Affiliations: Brigham and Women's Hospital (US)
Broad Institute (US)
Corresponding author: Ebert, Benjamin L
ORCID: Heckl, Dirk
Kowalczyk, Monika S
Yudovich, David
Belizaire, Roger
McConkey, Marie E
Aster, Jon C
Regev, Aviv
Ebert, Benjamin L
Venue: Nature Biotechnology
Publisher: Springer Science and Business Media LLC
Published: 2014-06-22
Volume: 32
Issue: 9
Pages: 941-946
ISSN: 0733-222X (ISSN-L)
1087-0156
1546-1696
DOI: 10.1038/nbt.2951
PMC: PMC4160386
OpenAlex: W1575193685
Cited by: 555
References: 27
Citations by year: 2026: 14 · 2025: 29 · 2024: 28 · 2023: 58 · 2022: 58 · 2021: 58 · 2020: 61 · 2019: 51 · 2018: 54 · 2017: 61 · 2016: 38 · 2015: 39 · 2014: 5
FWCI: 19.53
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Biotechnology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
Funders: National Heart, Lung, and Blood Institute (R01HL082945)
National Human Genome Research Institute (P50HG006193)
National Cancer Institute (P01CA108631, P01CA066996)
National Institute of General Medical Sciences (T32GM007753)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords: myeloid neoplasms, acute myeloid leukemia, mouse tumor model, CRISPR/Cas9 genome editing, lentiviral delivery, hematopoietic stem cells, clonal outgrowth, driver mutations, epigenetic regulators, transcription factors, cytokine signaling, cooperating mutations
MeSH terms: Animals, Disease Models, Animal, Bone Marrow Neoplasms, Mice, Clustered Regularly Interspaced Short Palindromic Repeats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks